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Several transplant patients maintain stable kidney graft
function in the absence of immunosuppression. Here we
compared the characteristics of their peripheral B cells
to that of others who had stable graft function but were
under pharmacologic immunosuppression, to patients with
chronic rejection and to healthy volunteers. In drug-free
long-term graft function (DF) there was a significant increase
in both absolute cell number and frequency of total B cells;
particularly activated, memory and early memory B cells.
These increased B-cell numbers were associated with
a significantly enriched transcriptional B-cell profile.
Costimulatory/migratory molecules (B7-2/CD80, CD40, and
CD62L) were upregulated in B cells; particularly in memory
CD19þ IgDCD38þ /CD27þ B cells in these patients.
Their purified B cells, however, responded normally to
a polyclonal stimulation and did not have cytokine
polarization. This phenotype was associated with the
following specific characteristics which include an inhibitory
signal (decreased FccRIIA/FccRIIB ratio); a preventive signal
of hyperactive B-cell response (an increase in BANK1, which
negatively modulates CD40-mediated AKT activation); an
increased number of B cells expressing CD1d and CD5;
an increased BAFF-R/BAFF ratio that could explain why
these patients have more peripheral B cells; and a
specific autoantibody profile. Thus, our findings show
that patients with DF have a particular blood B-cell
phenotype that may contribute to the maintenance of long-
term graft function.
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Organ transplantation is the treatment of choice for life-
sustaining terminal organ deficiencies. Nevertheless, preven-
tion of rejection requires nonspecific immunosuppression,
which increases the risk of complications such as infections,1
malignancies, and side effects.2 Moreover, immunosuppres-
sion poorly influences chronic rejection, the main cause of
graft loss in the long term.3 Thus, a major goal in
transplantation is to induce tolerance.
Tolerance to allografts was first described by Billingham
et al.4 more than 50 years ago. The definition of this ‘true’
tolerance has been proposed as a well-functioning graft
lacking histological lesions of rejection, in the absence of
immunosuppression in an immunocompetent host accepting
a second graft of the same donor, while able to reject a third-
party graft. In humans, we reported on a state of long-term
acceptance of mismatched kidney allografts after immuno-
suppressive drug withdrawal after kidney transplantation.5
Because several key elements of transplant tolerance in
rodents cannot be demonstrated in humans, this state has
been referred to as drug-free long-term graft function (DF).
For example, graft biopsies are often unavailable, particularly
given that this state of clinical tolerance has been observed by
chance and not in the context of planned tolerance-inducing
protocols and that these patients are usually incompliant and
refuse invasive investigative procedures.5 The mechanisms of
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this state of DF remain unknown. In particular, no significant
alteration in their T-cell phenotype or function has been
reported.6,7 In a previous paper, we showed that these
patients were characterized by a higher number of peripheral
B cells compared with both patients with stable graft function
under immunosuppression and patients with histological
signs of antibody-mediated chronic rejection.7 In this paper,
we analyzed the peripheral B cells of these patients in terms
of transcription and phenotype, as well as their capacity to
respond to short in vitro activation.
As these patients may not display an ‘optimal’ response to
alloantigens and rarely develop an alloimmune response,5 we
hypothesized that regulation and/or control of this response
may take place and that B cells could be involved in this
process of tolerance. Although B cells are primarily known
for their ability to differentiate into antibody-producing cells,
they display additional functions by producing cytokines and
functioning as antigen-presenting cells.8 Recent evidence
indicates that regulatory B cells can enhance tolerance,9–12
may control organ-specific inflammation driven by Th1,
Th2, or Th17 cell responses, or may directly interact with
other immune cells.10,13–15
RESULTS
DF patients display high numbers of B cells and particularly
Bm2, EBm5/Bm5 memory B cells
We used the Bm1–Bm5 classification system to identify B-cell
developmental stages in the blood of the patients. Bm3/Bm4
were not included in the analysis because they were absent in
the blood. We first confirmed that DF patients displayed a
significantly higher number (frequency, absolute value) of
peripheral B cells (Figure 1a and b). This increase in
circulating B cells was mainly due to a significant increase
in IgDþCD38þ (corresponding to activated Bm2 cells)
(Figure 1c) and IgDCD38þ / in absolute values (corres-
ponding to EBm5/Bm5 memory B cells that also express the
CD27 marker) (Figure 1d and e). No difference was observed
for the frequencies of other B-cell sub-populations. Despite a
small trend toward an increased number in DF patients, only
very low numbers of Bm20 cells and transitional B cells were
detected (limit of flow-cytometry sensitivity). Similarly, no
statistically significant difference was found with respect
to healthy volunteers (HV). Total B cells of DF patients
displayed a significantly higher level of CD80 (Po0.05),
CD86 (Po0.01), CD40 (Po0.05), and CD62L (Po0.05)
compared with other transplant patients (Figure 2a–d).
A significant difference toward HV was only found for
CD80. We then analyzed the mean fluorescence intensity
(MFI) of these markers within the gated CD19þ IgD
CD38þ / population. CD40 MFI was significantly increased
in IgDCD38þ / memory populations from DF patients
compared with the patients with stable graft function and HV
(Figure 2e). Altogether, these data show that DF patients
display a high number of circulating B cells expressing an
activated-memory phenotype with expression of costimula-
tory molecules.
DF patients display a B cell-enriched gene profile
We analyzed data from our previous pangenomic microarrays16
according to the B-cell signatures described in the literature.
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Figure 1 |Drug-free long-term graft function (DF) patients display a higher number of peripheral B cells. DF patients display a
significantly higher frequency (a) and absolute value (b) of total peripheral B cells. The increase of B cells in DF patients is mainly due to a
significant increase in IgDþCD38þ (activated Bm2 cells) (c) and IgDCD38þ / (EBm5/Bm5 memory B cells) (c). This was confirmed by an
increase of the number of memory CD19þCD27þ B cells in DF patients (e). Differences were defined as statistically significant when
Po0.05 (*), Po0.01 (**), and Po0.001 (***). CR, patients under standard immunosuppression with deteriorating kidney graft function;
HV, healthy volunteers; STA, kidney recipients with stable graft function under standard immunosuppression.
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Gene set enrichment analysis was used to identify enrichment of
genes related to B-cell pathways.17 Among the genes significantly
enriched (false discovery rateo25%, Po5%) in DF patients
compared with patients with stable graft function, seven
major sets of genes were related to B-cell pathways (Table 1
and Supplementary Figures SA–G).18–21 Genes that contri-
buted to the enrichment result were selected and their
biological function analyzed using Gominer software.22
Altogether, DF patients are characterized by a signi-
ficant regulation of several B-cell-associated subsets with
upregulation of genes related to cell cycle (CCNA2, CCND2,
BIRC5, CDC2, CDKN3, CKS2, PCNA), proliferation
(CCNA2, CDC20, BUB1), development, and maturation.
These findings largely reflect the ‘abnormal’ larger pool of
B cells (due to proliferation and increased cell cycling) in
DF patients.
B cells from DF patients display an inhibitory profile
We analyzed transcript level and/or surface expression of
molecules reported to be involved in inhibitory/regulatory
B-cell profiles. CD32 is a complex cluster of the low-affinity
FcgReceptor (FcgR). Although FcgRIIA (CD32a) transduces
an activator signal, FcgRIIB (CD32b) contains an immuno-
receptor tyrosine-based inhibition motif, transducing an
inhibitory signal upon co-ligation with the B-cell receptor.
Because the CD32a/CD32b ratio is a relevant index of B-cell
activation/inhibition, we analyzed this in the blood of our
patients. We found that DF patients had a significantly
decreased CD32a/CD32b ratio compared with patients with
chronic rejection (Po0.05) in total blood, and a trend for
a decreased CD32a/CD32b ratio was also observed at the level
of CD19þ B cells (reported to the CD19 gene) (Figure 3a
and b). Moreover, the significant increased CD32b mRNA in
total peripheral blood mononuclear cells fits with a trend
to higher expression (at the protein level by flow cytometry
both in absolute value and in MFI) of CD32b in DF patients
(Figure 3c–e).
Because the B-cell scaffold protein with ankyrin repeats 1
(BANK1) was highlighted as a leader gene in our previous
study,23 we looked at its expression in blood from our
patients. BANK1 is a negative modulator of CD40-mediated
AKT activation preventing hyperactive B-cell responses.24
We found a significant accumulation of BANK1 transcripts in
the blood of DF patients compared with stable patients
(Po0.01) and other controls (Po0.01, Po0.05) (Figure 4a).
The same tendency was observed when the BANK1 molecule
was analyzed in purified CD19þ B cells, suggesting that this
increased expression was not only due to a higher number of
B cells but a higher expression of BANK1 in B cells from DF
patients (Figure 4b). Finally, we looked at the surface expression
of CD1d and CD5 among CD19þ cells, two molecules
potentially involved in a regulatory phenotype.9,11 DF patients
had a significantly higher number of B cells expressing CD5
and CD1d compared with stable patients (Po0.05), both
in frequency and absolute values (Figure 4c and d).
Altogether, these data suggest that the B cells of DF
patients display an inhibitory profile.
DF patients are characterized by a transcriptional profile
favouring B-cell survival
Because of the increased B-cell number in DF patients,
we looked at key molecules involved in B-cell survival:
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Figure 2 |DF patients display a higher number of memory B cells that express markers of costimulation. Drug-free long-term
graft function (DF) patients display a significantly higher level of IgDCD38þ /CD80þ memory B cells (a), IgDCD38þ /CD86þ memory
B cells (b), IgDCD38þ /CD40þ memory B cells (c), and IgDCD38þ /CD62 Lþ memory B cells (d). Moreover, IgDCD38þ / memory
B cells from DF patients exhibit a significant higher level of CD40 markers at their surface (mean fluorescence intensity) (e). Differences were
defined as statistically significant when Po0.05 (*), Po0.01 (**), and Po0.001 (***).
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transmembrane activator and CAML interactor (TACI),
B-cell-activating factor receptor (BAFF-R), and B-cell
maturation protein (BCMA). Although BCMA and BAFF-R
are involved in B-cell survival, TACI is a negative regulator of
B-cell survival.25,26 BAFF–BAFF-R interactions were shown to
be crucial for maintaining normal peripheral B-cell num-
bers27 and instrumental for survival of memory B cells.28,29
We found that DF patients displayed an increased BAFF-R/
BAFF ratio compared with patients with stable graft function
(Po0.01), healthy individuals (Po0.05), and patients with
chronic rejection (Po0.05) that was correlated to a
significant upregulation of the TACI/BAFF signaling pathway
(Po0.05) (Figure 4e and f).
Together, these data suggest that DF patients are charac-
terized by a transcriptional profile favouring B-cell survival
that may contribute to their high B-cell number and trans-
criptional profile.
B cells from DF patients respond normally to in vitro
polyclonal activation
B cells from three DF patients, five patients with stable
graft function under immunosuppression, five HV and five
Table 1 | Description of gene sets (GS) related to B-cell pathways identified by gene set enrichment analysis in the blood of
patients with drug-free long-term graft function compared with patients with stable function under immunosuppression
Gene set name
Number
of genes NES
NOM
P-val
FDR
q-val Gene set description References
BASSO_REGULATORY_HUBS 61 1.80 0.006 0.21 Genes highly interconnected in the reconstructed regulatory
networks from expression profiles in human B cells.
Basso et al.18
HOFFMANN_BIVSBII_BI_TABLE2 100 1.73 0.005 0.19 Genes with at least fivefold change in expression
between pre-BI and large pre-BII cells.
Hoffmann
et al.19
TARTE_PLASMA_BLASTIC 160 1.71 0.014 0.20 Genes overexpressed in mature plasma cells isolated
from tonsils and mature plasma cells isolated from bone
marrow as compared with polyclonal plasmablastic cells.
Tarte et al.21
ZHAN_MM_CD138_PR_VS_REST 22 1.70 0.014 0.21 50 top ranked overexpressed genes in each of the seven
subgroups of multiple myeloma in CD138-enriched
plasma cells from 414 newly diagnosed patients.
Zhan F et al.,
Blood 2006
GREENBAUM_E2A_UP 15 1.54 0.014 0.24 Genes upregulated at least threefold in the E2A-deficient
cell lines.
Greenbaum
et al.20
HOFFMANN_BIVSBII_LGBII 60 1.53 0.013 0.24 Genes with at least fivefold change in expression
between large and small pre-BII cells.
Hoffmann
et al.19
TARTE_PC 38 1.59 0.015 0.25 Genes overexpressed in polyclonal plasmablastic cells,
mature plasma cells isolated from tonsils and mature
plasma cells isolated from bone marrow as compared
with B cells purified from peripheral blood and tonsils.
Tarte et al.21
The size is the number of genes in the gene set after filtering out those genes not in the expression data set. The normalized enrichment score (NES) is the degree to which a
gene set is overrepresented, normalized across analyzed gene sets. The nominal P-value (NOM P-val) is the statistical significance of the enrichment score. The false discovery
rate (FDR) is the estimated probability that the normalized enrichment score represents a false-positive finding.
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Figure 3 |DF patients display B cells with an inhibitory profile. (a) Peripheral blood mononuclear cells (PBMCs) from drug-free long-term
graft function (DF) patients display a significantly decreased CD32a/CD32b FcgRIIA/FcgRIIB transcript ratio both at the level of total
PBMC (a) and at the level of CD19þ B cells (b) compared with patients with chronic rejection and healthy volunteers, respectively. Among
total PBMC, DF patients express higher number of CD19þ FcgRIIBþ (CD32b) B cells as shown by flow cytometry (c) and a significant
increase in FcgRIIB (CD32b) mRNA expression (d). Finally, B cells from DF patients tend to express more FcgRIIB (CD32b) at their surface
(mean fluorescence intensity) (e). Differences were defined as statistically significant when Po0.05 (*), Po0.01 (**), and Po0.001 (***).
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patients with chronic rejection were isolated and activated
using different stimuli (CD40 ligand, CD40 ligandþ anti-
IgM, CD40 ligandþCpG) over 4 time points (0, 16, 24, 40 h,
following stimulation). CD25 and CD80 expression was
analyzed (MFI and frequency) to control B-cell activation
(Figure 5). We analyzed by Luminex xMAP technology the
level of interleukin (IL)10, transforming growth factorb, IL4,
IL6, tumor necrosis factora, IL2R, interferong, and IL6R in
the supernatants of B-cell cultures 40 h after activation.
Before and after activation, only low levels of IL4,
transforming growth factorb, IL6R, IL2R, and interferong
were detectable in supernatants from all groups of patients.
After 40 h of activation and independently of the stimuli, no
difference was observed for IL10, IL6, and tumor necrosis
factora levels for the different groups of patients (Figure 6).
Altogether, no absence of response or cytokine polarization
was observed in the conditions of stimulation used in DF
patients compared with HV and other recipients.
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Figure 4 |DF patients display B cells with an inhibitory profile and profile of B cell survival. (a) Blood from drug-free long-term graft
function (DF) patients is characterized by a significant accumulation of BANK1 transcripts, a negative modulator of CD40-mediated AKT
activation, thereby preventing hyperactive B-cell responses. (b) The same tendency is observed in purified CD19þ B cells (b). DF patients
display a significantly higher number of B cells expressing the CD5 (c) and CD1d markers (d). DF patients are characterized by an upregulation
of the BAFF-R/BAFF ratio (e) and an upregulation of the TACI/BAFF signaling pathways (f). Differences were defined as statistically
significant when Po0.05 (*), Po0.01 (**), and Po0.001 (***).
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Figure 5 |B cell activation. Cultured blood B cells were incubated with anti-CD25 (a) or anti-CD80 (b) to assess B-cell activation after 40 h
culture with CD40L alone, CD40L and CpG or CD40L and antihuman immunoglobulin M (IgM).
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Development of allo- and autoantibodies in DF patients
We studied anti-donor antibodies by applying the Luminex
Single antigen technique to sera from DF patients (Labscreen
Single Antigen; One lambda, Canoga Park, CA, USA).
Out of the 12 DF patients (mismatched cadaveric graft), 10
displayed no anti-human leukocyte antigen antibodies and
2 displayed anti-donor antibodies (DQ7 and A33/DQ8).
The MFI were 21,800 for DQ7, and 9200 and 193,00 for A33
and DQ8, respectively (Table 2, Supplementary Table SD).
It has been suggested that patients submitted to a tolerance
induction protocol develop a substantial autoimmune
response.30 We investigated whether DF patients also
exhibited an autoimmune component using protein micro-
arrays. Although each individuals exhibit high numbers
of potential autoantibodies (mean¼ 3921, s.e.m.¼ 320, at a
threshold of 500 relative fluorescence units (RFU)), the
number of total autoantibodies measured for the four groups
of individuals was not statistically different, whatever the
threshold used (Supplementary Figure SH). Similarly, when
the autoantibody signal for HV was subtracted to analyze
only autoantibodies due to transplantation, the number of
autoantibodies in each group remained not significantly
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Figure 6 |B cells from three drug-free long-term graft function (DF) patients, five patients with stable graft function, five healthy
volunteers and five patients with chronic rejection were purified from peripheral blood mononuclear cells by negative selection.
B cells were either unstimulated or stimulated with CD40L alone, CD40L and CpG or CD40L and anti-human immunoglobulin M (IgM).
Supernatants were collected at different time points (0, 16, 24, and 40 h after stimulation). Aliquots of the supernatant were analyzed for
different cytokines (data are presented for interleukin (IL)-6, IL-10, and tumor necrosis factor (TNF)a), by Luminex xMAP technology. Results
were shown after 40 h of activation.
508 Kidney International (2010) 78, 503–513
or ig ina l a r t i c l e A Pallier et al.: Drug-free recipients display a B-cell inhibitory phenotype
different (Supplementary Figure SI). Because the spectrum of
specificity of these autoantibodies could vary in each group
and individual, M-statistics were performed using the
Protoarrays manufacturer’s software to identify differentially
expressed antoantibodies in DF patients. Among the 98
targets with a P-value inferior to 0.01, 51 targets (48 unique
proteins) exhibited a higher prevalence in the DF group
and 47 targets (44 unique proteins) in other groups
(Supplementary Tables SA and SB). For both lists, no unique
pathway or biological process was highlighted, whereas
ontologies such as phosphorylation (GO: 0016310) and
signal transduction (GO:0007165) were enriched for targets
with lower prevalence in the DF group (false discovery rate
o0.01) using Gominer software. Furthermore, among the
92 proteins, 36 are known to be expressed by the kidney.31
Focusing on particular proteins, autoantibodies against
proteins known to be expressed in B cells were identified:
CHEK1, PIM2, LCK, ZAP70, IKBKB, PDGFRA, PSMA4, and
LPXN (Supplementary Figure SJ).
DISCUSSION
We previously reported that DF patients are characterized by
a high number of peripheral B cells.7 This observation was
confirmed by two international networks (M. Hernandez-
Fuentes and KA Newell, Am Transplant Congress, Boston,
2009) in kidney recipients, whereas no increase was observed
in drug-free patients after a liver transplantation.32 This
increased number of B cells was supported by an enriched
B-cell transcriptional profile not only compared with
patients with chronic rejection, as confirmed by others
(M. Hernandez-Fuentes and KA Newell, Am Transplant
Congress, Boston, 2009) but also compared with stable
patients under immunosuppression.
These observations led us to perform a detailed analysis of
the B-cell compartment in DF patients, compared with stable
patients under immunosuppression. Ever since the first cases
of operational tolerance in the clinic were described, the
problem of adequate comparators has remained unsolved.
This paradox is due to the clinical situation of these patients
that display stable graft function but no longer receive
immunosuppression, a state that, until now, was only
achievable in rodents. HV share with DF patients the absence
of immunosuppression but have not received a transplant.
Patients with chronic rejection have a transplant but are
under immunosuppression and likely display a contrasted
inflammatory response. Stable patients who share graft
function stability with DF patients are probably the best
controls but are under immunosuppression. Finally, it may
be useful to compare the profile of DF patients with chronic
rejection because no biopsy was available for DF patients in
whom a ‘minimal’ form of subclinical chronic rejection
cannot be excluded.
We report that DF patients are characterized by a signi-
ficant increase in absolute value (not in frequency) of
memory B cells that express costimulatory/migratory mole-
cules, compatible with an inhibitory/regulatory B-cell profile.
Table 2 | Summary of clinical data: patients with drug-free long-term graft function (DF), kidney recipients with stable graft
function under standard immunosuppression (STA), patients under standard immunosuppression with deteriorating kidney
graft function (CR) and healthy volunteers (HV)
Groups
Age
(years)
Gender
(female/all)
Time between
graft and
analysis (months)
Creatinemia
(lmol/l)
Proteinuria
(g/24h)
Donor (living
vs deceased)
Number
of HLA
mismatches
Time between immuno-
suppression withdrawal
and analysis (years)
Donor
specific Abs
DF
Mean 52 3/12 177 100 0.12 1/12 3 8 2/12
s.d. 18 97 36 0.20 2 8
Min 27 3 59 35 0.00 1 0 3 2
Max 82 9 368 142 0.59 11 4 27 10
CR
Mean 54 17/31 102 256 3 1/31 3
s.d. 14 69 99 3 2
Min 27 14 20 84 0 1 0
Max 78 17 304 492 12 30 6
STA
Mean 49 12/34 123 121 0 3/34 3
s.d. 14 67 34 0 1
Min 24 12 29 68 0 3 0
Max 76 22 269 215 1 30 6
HV
Mean 44 13/29
s.d. 11
Min 25 13
Max 66 16
Abbreviations: Abs, antibodies; HLA, human leukocyte antigen.
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These changes were significant not only compared with stable
patients under immunosuppression but also patients with
histologically proven signs of chronic rejection, a cohort of
patients where enhanced B-cell activity was expected. These
observations led us to hypothesize that B cells could
contribute to the maintenance of long-term graft function.
The imbalanced and decreased CD32a/CD32b ratio in DF
patients suggests that some mechanisms of regulation by the
low-affinity type IIb immunoglobulin G (IgG) Fc-binding
(CD32b)33–37 overcome activation mediated by CD32a.
Interestingly, DF patients also exhibited an upregulation
of the peripheral BAFF-R/BAFF ratio that is crucial for the
maturation of B cells and for maintaining peripheral B-cell
numbers.28,29,38,39 In support of these data, we report that
genes related to B-cell cycle were also overexpressed in DF
patients. Finally, TACI/BAFF ratio was also increased in these
patients suggesting that B cells remain under the control of
TACI, a negative regulator of mature B cells40 and that these
observations do not reflect a general deregulation of B-cell
factors. We previously reported that BANK1 was one of the
key leader genes upregulated in DF patients.23 BANK1 is an
adaptor protein highly expressed in peripheral B cells41 that is
a modulator of hyperactive B-cell responses by inhibiting
AKT activation upon CD40 signaling.24 DF patients, both at
the peripheral blood mononuclear cells and B-cell level,
displayed a higher level of BANK1 transcripts than HV
suggesting that, again, this profile is not linked to the absence
of treatment. DF patients also displayed B cells expressing the
CD1d and CD5 molecules. Recently, a CD1dh CD5þ B-cell
subset producing IL10 has been identified as a unique subset
of potent regulatory B cells in mouse42 and in human.43
CD1d is also important for the generation of an optimal Th2
T-cell response44 that promotes a favorable context for
tolerance.45 Nevertheless, B cells from DF patients only
produced low levels of IL10 after 40 h activation and no
difference was observed between the groups of patients and
HV in terms of IL4, IL6R, IL2R, tumor necrosis factora,
transforming growth factorb, and interferong production.
These data show that B cells from DF patients are not
hyporesponsive to polyclonal activation and display a similar
pattern of activation as the other patients after short in vitro
activation.
Finally, we looked at the development of allo- and auto-
antibodies in DF patients. To date, 11 of these 12 patients still
display stable graft function and are immune-competent
decades after transplantation.46 Two displayed antibodies
reacting with donor major histocompatibility complex (DQ7
and A33/DQ8). One patient still has a stable function 6 years
after antibody appearance. The second rejected his graft
4 years after interruption of immunosuppression (12 years
after transplantation) and 2 years after appearance of
antibodies. A biopsy for the latter patient revealed lesions
of transplant glomerulopathy without C4d staining. Finally,
we investigated whether DF patients also exhibited an
autoimmune component as previously described in induced
‘tolerant’ patients.30 Consistent with previous knowledge, we
found that all individuals, even HV, exhibit antibodies
directed against a wide spectrum of antigens, such as
internal, cell surface, circulating proteins, carbohydrates,
nucleic acids, lipids, and haptens.47 We also found that
DF patients were not characterized by a different level of
circulating autoantibodies but could have different specific
autoantibodies. Indeed, while Li et al.31 demonstrated an
enrichment of kidney-specific autoantibodies produced after
renal transplantation, there was the same proportion of
produced autoantibodies between the different groups of
recipients. Interestingly, we identified 98 autoantibody targets
with significantly higher or lower prevalence in DF patients
compared with the others. However, no clear pathway was
identified arguing that autoantibody production could not
belong to a mainstream biological process. Focusing on
particular proteins, autoantibodies against proteins expressed
in B cells were identified such as CHEK1, PIM2, LCK, ZAP70,
IKBKB, PDGFRA, and LPXN. Thus, CHEK1 autoantibody
exhibited a higher prevalence in the DF group and its gene
was found to be overexpressed in our previous study.16
Furthermore, Porcheray et al.30 found that PSMA4 autoanti-
body was highly expressed in one tolerant patient and we also
found that PSMA4 autoantibody was highly expressed in one
DF patient and expressed less in all other patients. Finally, we
found that Leupaxin, a member of the paxillin superfamily,
was one of the autoantibodies largely increased in DF
patients. This molecule, which is preferentially expressed in
hematopoietic cells including B cells, has been shown to
suppress the secretion of IL2, likely by the inhibition of JNK,
p38 MAPK, and AKT signaling. This molecule thus has
an inhibitory role in BCR signaling and B-cell function.48
Overall, our study points to several characteristics in
B cells from DF patients. Further studies are required to
explore if B cells are indeed involved in long-term graft
acceptance decades after withdrawal of immunosuppression.
MATERIALS AND METHODS
Patients
The study was approved by the University Hospital Ethical
Committee and the Committee for the Protection of Patients from
Biological Risks. All 106 age-matched kidney transplant patients
included for study gave informed consent (Table 2 and Supple-
mentary Tables SC and SD).
(i) Patients with DF (n¼ 12): patients with a stable kidney graft
function (creatinemia o150mmol/l and proteinuria o1g/24 h) in
the absence of immunosuppression for at least 1 year (range: 3–21
years).16 Treatment was stopped due to non-compliance (n¼ 9),
post-transplant lymphoproliferative disorder (n¼ 2), or calcineurin
inhibitor toxicity (n¼ 1). (ii) Kidney recipients with stable graft
function under standard immunosuppression (STA; n¼ 34): had
a creatinemia o150 mmol/l and proteinuria o1 g/24 h for at least
3 years. (iii) Patients under standard immunosuppression with
deteriorating kidney graft function (CR; n¼ 31): with a creatinemia
4150 mmol/l and/or proteinuria 41 g/24 h, classified according to
the Banff classification criteria.49,50 Five out of the 31 patients had
a transplant glomerulopathy, 18/31 were suspicious for humoral
rejection (C4d or circulating anti-human leukocyte antigen
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antibodies), 8/31 had an active humoral component (C4d and
circulating anti-donor antibodies). (iv) HV (n¼ 29): age-matched
healthy volunteers (mean age: 44±11 years; range 25–66; sex
16M/13F) had a normal blood formula and no infectious or other
concomitant pathology for at least 6 months before the study.
Biological samples
Venous blood samples were collected in EDTA vacutainers.
Peripheral blood mononuclear cells were separated on a Ficoll layer
(Eurobio, Les Ulis, France) and frozen in TRIzol reagent (Invitrogen,
Cergy Pontoise, France).
RNA cDNA and real-time quantitative PCR
RNAwas extracted using the TRIzol method (Invitrogen), according
to manufacturer’s instructions. Genomic DNA was removed by
DNase treatment (Roche, Indianapolis, IN, USA). RNA quality
and quantity was determined using an Agilent 2100 BioAnalyzer
(Palo Alto, CA, USA). RNA was reverse transcribed using polydT
oligonucleotide and Maloney leukemia virus reverse transcription
(Invitrogen). Real-time quantitative PCRwas performed using
commercially available primer and probe sets HPRT:
Hs99999909_m1, CD32a: Hs00234969_m1, CD32b: Hs00269610_m1,
BANK1: Hs00215678_m1, BAFF-R: Hs00606874_g1, BAFF:
Hs00198106_m1, APRIL: Hs00742713_s1, TACI: Hs00963364_m1,
BCMA: Hs03045080_m1, CD19: Hs00174333_m1 from Applied
Biosystems (Foster City, CA, USA). HPRT and CD19 were used as
endogenous controls to normalize RNA amounts. Relative expression
between a sample and a reference was calculated according to the
2DDCt method.51
Flow cytometry
The mature Bm cell sub-populations were studied according to their
expression of CD38, IgD, and CD27.52,53 Flow cytometry was
performed on a BD LSRII analyzer with FlowJo software (TriStar
Inc., Ashland, OR, USA) using monoclonal antibodies: CD19 (IgG1/
J4.119), CD38 (IgG1/HIT2), IgD (IgG2a/IA6), CD80 (IgG1/L307.4),
CD86 (IgG1/IT2.2), CD27 (IgG1/M-T271), CD5 (IgG1/UCHT2),
CD40 (IgG1/5C3), CD62 L (IgG1/Dreg56), IgM (IgG1/G20-127),
CD21 (IgG1/IV B98), CD138 (IgG1/BP100), CD1d (IgG1/M-T101)
(BD PharMingen, San Diego, CA, USA), CD32 (IgG2a/2E1) and
CD20 (IgG1/B9E9) (Immunotech, Luminy, France).
Microarray data analysis
Raw gene-expression files16 are available at the Stanford Micro-
array Database http://smd.stanford.edu/cgi-bin//publication/view-
Publication.pl?pub_no=654. Gene set enrichment analysis (http://
www.broad.mit.edu/gsea/) was run on 4942 genes by using version
2.5 of the C2 gene set database and the 1252 gene sets comprising
more than 10 and less than 500 genes were used. Default parameters
and 10,000 random sample label permutations were used. Gene sets
with a false discovery rate inferior to 25% and a nominal P-value
inferior to 5% were selected. Gominer software22 was performed to
investigate biological processes and functions and to group the genes
into biologically coherent categories.
Detection of alloantibodies
Human leukocyte antigen antibodies were detected by a multiplex
screening test (LAT-M; One lambda, Canoga Park, CA, USA).
Donor-specific antibodies were detected by Luminex Single antigen
(Labscreen Single Antigen).
Autoantibody immunoprofiling
Serum immunoprofiling was performed on ProtoArray
human protein microarrays v4.0 by the ProtoArray Service team
(Invitrogen). Each microarray contained approximately 8000
recombinant proteins spotted in duplicate. One ProtoArray was
used per sample and a negative control assay (buffer with no serum)
was run in parallel. Microarray slides were prepared according to the
manufacturer’s protocol. Arrays were scanned using an Axon
GenePix 4000B fluorescent microarray scanner, and data extraction
was performed using GenePix Pro 6.0 software (Molecular Devices,
Sunnyvale, CA, USA). Microarray quantile normalization, back-
ground subtraction, and average calculation of duplicates were
performed using Invitrogen’s proprietary Protoarray Prospector
Software v5.2.1 and then the signal from the negative control array
was subtracted from each slide. To compare the level of total
autoantibody in each group, we compared the number of targets at
multiple thresholds of RFU, according to the fact that the filtering
procedure could induce a bias31 (Supplementary Figure SH). To
analyze autoantibodies due to transplantation, the mean signal of
healthy volunteers was subtracted for each patient array (delta
intensity signal). Potential autoantibodies were selected if the
delta intensity signal was superior to given thresholds fixed at 0,
50, (ref. 30) 100, 500, (ref. 54) 1000 or 5000 RFU (Supplementary
Figure SI). To identify autoantibodies specific to DF patients, a
statistical analysis was performed using Protoarray Prospector
Software and M-statistics according to Babel et al.55 To select
reliable autoantibodies and following the manufacturer recommen-
dations, additional thresholds were imposed requiring that signals
be at least 500 RFU and a minimum signal difference of 200RFU
had to be observed between samples from DF patients and samples
from the other groups.
B-cell activation
B cells were purified by negative selection using magnetic beads
(Dynabeads; Invitrogen, Paisley, UK) in accordance with manufac-
turer’s instructions. Purification was typically 97% CD19þ . B cells
were stimulated with CD40L (Alexis biochemical; Enzo Life Sciences
Inc., Farmingdale, NY, USA), CD40L, and CpG ODN 2006 (Hycult
biotechnology; Uden, The Netherlands) or CD40L and anti-human
IgM (Jackson ImmunoResearch Lab, West Grove, PA, USA). B cells
were incubated with conjugated antibodies (all from BD Pharmin-
gen, San Diego, CA, USA): anti-CD19, anti-CD80, and anti-CD25.
Supernatants were collected at 0, 16, 24, and 40 h following stimula-
tion and analyzed for cytokines (IL-4, IL-6, IL-10, tumor necrosis
factora, interferong, IL-2Ra, IL-6R, and transforming growth factorb1)
by Luminex xMAP technology (MILLIPLEX MAP; Millipore, Billerica,
MA, USA), in accordance with manufacturer’s protocol.
Statistical analysis
The non-parametric Kruskal–Wallis test with Dunn0s post-test was
used for comparison of more than two groups using GraphPad
Prism software v.4. Differences were defined as statistically
significant when Po0.05 (*), Po0.01 (**), and Po0.001 (***).
Correlations were analyzed by linear regression and mean values
were compared using the Mann–Whitney test or Wilcoxon’s test for
paired series. Categorical variables were compared by the w2-test
with the Yates correction when at least one of the calculated figures
was o5.
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SUPPLEMENTARY MATERIAL
Table SA. 51 targets of autoantibodies with higher prevalence in the
DF group compared to the other groups identified with M-statistics
with P-values inferior to 0.01.
Table SB. 47 targets of autoantibodies with lower prevalence in the
DF group compared with the other groups identified with M-statistics
with P-values inferior to 0.01.
Table SC. Description of the patient groups included for study: 31
patients under standard immunosuppression with deteriorating
kidney graft function (CR) and 34 kidney recipients with stable graft
function under standard immunosuppression (STA).
Table SD. Description of the patient groups included for study: 12
patients with drug-free long-term graft function (DF) and 29 healthy
volunteers (HV).
Figure SA–SG. Heat maps of the seven sets of genes related to B cell
pathways of 61,100, 160, 22, 15, 60, and 38 genes identified with
gene set enrichment analysis in the blood of patients with drug-free
long-term graft function compared with patients with stable function
under immunosuppression.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
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